View web version.
Learn more to identify the role of NGS and frequency
of incidental germline findings in tumor testing

The Evolving Role of NGS and Germline Sequencing in Patients with Advanced and Metastatic Cancer

Tuesday, June 29, 2021 • 7:00pm – 8:15pm ET

Objectives:

  • Identify the role of NGS and frequency of incidental germline findings in tumor testing
  • Examine the value of tumor/normal sequencing for metastatic cancer patients with incidental germline findings
  • Obtain insight on how physicians interpret incidental germline findings and the impact on decision making
Register Now

Speakers:

Mark Robson, MD

Chief, Breast Medicine Service

Memorial Sloan Kettering Cancer Center

 

 

John Henson, MD

Senior Genetic Counselor

Penn Medicine

 

 

Dana Farngo Clark, MS, LCGC

Professor of Neurology, Medicine, and Neurosurgery

Augusta University

 

 

Ashley Ross, MD, PhD

Associate Professor of Urology

Northwestern Medicine

Feinberg School of Medicine

 

 
 
This email was sent by: %%Member_Busname%%
%%Member_Addr%%, %%Member_City%%, %%Member_State%%, %%Member_PostalCode%% %%Member_Country%%

Privacy Policy

Update Profile      Manage Subscriptions      Unsubscribe